http://sdbn.org sdbn.org Fri, 19 Mar 2010 02:51:52 +0000 http://backend.userland.com/rss092 en Elcelyx Therapeutics of San Diego has raised $1.2 million of a planned $2.2 million equity offering, according to an SEC filing. The document says the company’s president is Alain D. Baron,... [[Click headline to continue reading.]] http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/QjI8tDuiC9s/ After three tries, Somaxon Pharmaceuticals has won FDA approval for its insomnia drug. The San Diego-based biotech company said today it has gotten clearance to start selling doxepin (Silenor) in the... [[Click headline to continue reading.]] http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/V4Y8VjoFieE/ It must be nice to be the CEO of a life sciences company that sells itself. When Tina Nova stepped up to the microphone at the Roth Capital Partners Growth Stock Conference in Laguna Niguel, CA,... [[Click headline to continue reading.]] http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/OEHQV_CyQqM/ Regulatory news dominated the headlines in the past week. We have it summarized for you here. —Sequenom (NASDAQ: SQMN) said a lack of adequate controls, protocols and supervision were to blame... [[Click headline to continue reading.]] http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/I6eSsD8Rdd8/ SAN DIEGO, March 17, 2010 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today reported positive preliminary results from a Phase Ib clinical trial to evaluate the safety ... http://www.biospace.com/news_story.aspx?StoryID=174363&full=1 SAN DIEGO, March 17, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR) today announced that NASDAQ has approved its application to transfer its stock listing to The Nasdaq Capital Market (the "Capital Market") from The Nasdaq Global Market, effective at the opening of business on March 18, 2010. The company's ... http://www.biospace.com/news_story.aspx?StoryID=174361&full=1 SAN DIEGO, CA March 18, 2010- Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance. Sleep maintenance difficulty, defined as waking ... http://www.biospace.com/news_story.aspx?StoryID=174419&full=1 OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB: ISCO), www.internationalstemcell.com, announced today that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of California, Irvine (UCI), is starting a second phase of essential pre-clinical experiments to test retinal pigment epithelium derived from parthenogenetic... http://www.biospace.com/news_story.aspx?StoryID=174402&full=1 SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the fourth quarter... http://www.biospace.com/news_story.aspx?StoryID=174427&full=1 SAN DIEGO, March 18, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, March 23, 2010, at 5:15 p.m. Eastern Time (2:15 p.m. Pacific Time) at the Loews Miami Beach Hotel in ... http://www.biospace.com/news_story.aspx?StoryID=174432&full=1